Immunotherapy with interleukin-18 in combination with preoperative chemotherapy with ifosfamide effectively inhibits postoperative progression of pulmonary metastases in a mouse osteosarcoma model

Tumor Biology

Volumn 30, Issue 4, 2009, Pages 176-184

  Yamada, Naoko ^a   Hata, Masaki ^a   Ohyama, Hideki ^a   Yamanegi, Koji ^a   Kogoe, Nahoko ^a   Nakasho, Keiji ^a   Futani, Hiroyuki ^a   Okamura, Haruki ^a   Terada, Nobuyuki ^a  

^a HYOGO COLLEGE OF MEDICINE   (Japan)

Author keywords

Chemotherapy, preoperative; Ifosfamide; Immunotherapy; Interleukin 18; Metastasis, pulmonary; Osteosarcoma

Indexed keywords

IFOSFAMIDE; RECOMBINANT INTERLEUKIN 18;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CANCER SURGERY; CD8+ T LYMPHOCYTE; CELL FUNCTION; CONTROLLED STUDY; DISEASE MODEL; DRUG EFFECT; DRUG MECHANISM; FEMALE; IMMUNOTHERAPY; LUNG METASTASIS; MORTALITY; MOUSE; NATURAL KILLER CELL; NONHUMAN; OSTEOSARCOMA; POSTOPERATIVE PERIOD; PREOPERATIVE PERIOD; PRIORITY JOURNAL; TUMOR GROWTH;

ANIMALS; BONE NEOPLASMS; CELL LINE, TUMOR; DISEASE PROGRESSION; FEMALE; IFOSFAMIDE; IMMUNOTHERAPY; INTERLEUKIN-18; MICE; MICE, INBRED C3H; OSTEOSARCOMA; RECOMBINANT PROTEINS;

EID: 69749102736     PISSN: 10104283     EISSN: None     Source Type: Journal    
DOI: 10.1159/000236410     Document Type: Article

References (30)

1. Unni KK, Inwards CY, Bridge JA, Kindblom LG, Wold LF: Tumors of the Bones and Joints. AFIP Atlas of Tumor Pathology. Washington, American Registry of Pathology and Armed Forces Institute of Pathology, 2005, ser 4, fasc 2.
2. Picci P: Osteosarcoma (osteogenic sarcoma). Orphanet J Rare Dis 2007; 2: 6.
3. Bacci G, Lari S: Current treatment of high grade osteosarcoma of the extremity. J Chemother 2001; 13: 235-243.
4. Ferguson WS, Goorin AM: Current treatment of osteosarcoma. Cancer Invest 2001; 19: 292-315.
5. Bacci G, Ferrari S, Mercuri M, Longhi A, Fabbri N, Galletti S, Forni C, Balladelli A, Serra M, Picci P: Neoadjuvant chemotherapy for osteosarcoma of the extremities in patients aged 41-60 years: outcome in 34 cases treated with adriamycin, cisplatinum and ifosfamide between 1984 and 1999. Acta Orthop 2007; 78: 377-384.
6. Mori K, Rèdini F, Gouin F, Cherrier B, Heymann D: Osteosarcoma: current status of immunotherapy and future trends. Oncol Rep 2006; 15: 693-700.
7. Lebel-Binary S, Berger A, Zinzindohoué F, Cugnenc PH, Thiounn N, Fridman WH, Pagés F: Interleukin-18: biological properties and clinical implications. Eur Cytokine Netw 2000; 11: 15-26.
8. Hodge DL, Subleski JJ, Reynolds DA, Buschman MD, Schill WB, Burkett NW, Malyguin AM, Young HA: The proinflammatory cytokine interleukin-18 alters multiple signaling pathways to inhibit natural killer cell death. J Interferon Cytokine Res 2006; 26: 706-718.
9. Li W, Kashiwamura S, Ueda H, Sekiyama A, Okamura H: Protection of CD8+ T cells from activation-induced cell death by IL-18. J Leukoc Biol 2007; 82: 142-151.
10. Goab J: Interleukin-18 - interferon- inducing factor: a novel player in tumor immunotherapy. Cytokine 2000; 12: 332-338.
11. Yamashita K, Iwasaki T, Tsujimura T, Sugihara A, Yamada N, Ueda H, Okamura H, Futani H, Maruo S, Terada N: Interleukin-18 inhibits lodging and subsequent growth of human multiple myeloma cells in the bone marrow. Oncol Rep 2002; 9: 1237-1244.
12. Okamoto T, Yamada N, Tsujimura T, Sugihara A, Nishizawa Y, Ueda H, Kashiwamura S, Tsutsui H, Futani H, Maruo S, Okamura H, Terada N: Inhibition by interleukin-18 of the growth of Dunn osteosarcoma cells. J Interferon Cytokine Res 2004; 24: 161-167.
13. Cao R, Farnebo J, Kurimoto M, Cao Y: Interleukin- acts as an angiogenesis and tumor suppressor. FASEB J 1999; 13: 2195-2202.
14. Nakamura Y, Yamada N, Ohyama H, Nakasho K, Nishizawa Y, Okamoto T, Futani H, Yoshiya S, Okamura H, Terada N: Effect of interleukin-18 on metastasis of mouse osteosarcoma cells. Cancer Immunol Immunother 2005; 55: 1151-1158.
15. Asai T, Ueda T, Itoh K, Yoshioka K, Aoki Y, Mori S, Yoshikawa H: Establishment and characterization of a murine osteosarcoma cell line (LM8) with high metastatic potential to the lung. Int J Cancer 1998; 76: 418-422.
16. Osaki T, Péron JM, Cai Q, Okamura H, Robbins PD, Kurimoto M, Lotze MT, Tahara H: IFN-gamma-inducing factor/IL-18 administration mediates IFN-gamma- and IL-12- independent antitumor effects. J Immunol 1998; 160: 1742-1749.
17. Smyth MJ, Crowe NY, Godfrey DI: NK cells and NKT cells collaborate in host protection from methylcholanthrene-induced fibrosarcoma. Int Immunol 2001; 13: 459-463.
18. Gorelik E, Segal S, Feldman M: Growth of a local tumor exerts a specific inhibitory effect on progression of lung metastases. Int J Cancer 1978; 21: 617-625.
19. Fisher B, Gunduz N, Coyle J, Rudock C, Saffer E: Presence of a growth-stimulating factor in serum following primary tumor removal in mice. Cancer Res 1989; 49: 1996-2001.
20. Prehn RT: The inhibition of tumor growth by tumor mass. Cancer Res 1991; 51: 2-4.
21. Tsunemi T, Nagoya S, Kaya M, Kawaguchi S, Wada T, Yamashita T, Ishi S: Postoperative progression of pulmonary metastasis in osteosarcoma. Clin Orthop Relat Res 2003; 407: 159-166.
22. O'Reilly MS, Holmgren L, Shing Y, Chen C, Rosenthal RA, Moses M, Lane WS, Cao Y, Sage EH, Folkman J: Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 1994; 79: 315-328.
23. O'Reilly MS, Holmgren L, Chen C, Folkman J: Angiostatin induces and sustains dormancy of human primary tumors in mice. Nat Med 1996; 2: 689-692.
24. Gohongi T, Fukumura D, Boucher Y, Yun CO, Soff GA, Compton C, Todoroki T, Jain RK: Tumor-host interactions in the gallbladder suppress distal angiogenesis and tumor growth: involvement of transforming growth factor beta1. Nat Med 1999; 5: 1203-1208.
25. Holmgren L, O'Reilly MS, Folkman J: Dormancy of micrometastasis: balanced proliferation and apoptosis in the presence of angiogenesis suppression. Nat Med 1995; 1: 149-153.
26. Kaya M, Wada T, Nagoya S, Yamashita T: Prevention of postoperative progression of pulmonary metastases in osteosarcoma by antiangiogenic therapy using endostatin. J Orthop Sci 2007; 12: 562-567.
27. Kaya M, Wada T, Nagoya S, Kawaguchi S, Isu K, Yamashita T: Concomitant tumour resistance in patients with osteosarcoma: a clue to a new therapeutic strategy. J Bone Joint Surg Br 2004; 86: 143-147.
28. Merchant MS, Melchionda F, Sinha M, Khanna C, Hekman L, Mackall CL: Immune reconstitution prevents metastatic recurrence of murine osteosarcoma. Cancer Immunol Immunother 2007; 56: 1037-1046.
29. Zou W: Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nat Rev Cancer 2005; 5: 263-274.
30. Robertson MJ, Kirkwood JM, Logan TF, Koch KM, Kathman S, Kirby LC, Bell WN, Thurmond LM, Weisenbach J, Dar MM: A dose-escalation study of recombinant human interleukin-18 using two different schedules of administration in patients with cancer. Clin Cancer Res 2008; 14: 3462-3469.